Afya reinstated with a Buy at BofA » 09:2901/2301/23/20
BofA analyst Bruno…
BofA analyst Bruno Giardino reinstated coverage of Afya with a Buy rating and $35 price target. He views Afya as a premium higher education player given its high exposure to medicine courses and as such thinks the stock deserves a premium valuation, Giardino tells investors.
|Over a week ago|
Afya announces CFO transition plan » 06:3101/1301/13/20
Afya announced that…
Afya announced that Luciano Toledo de Campos, its CFO, notified the company of his intention to leave for personal reasons. Campos will remain with the company serving as CFO to ensure a smooth and effective transition of his duties, including through its scheduled FY19 financial results announcement. Afya has already started conducting a search for its next CFO. The company confirm that the transition is not related to any matter regarding the company's financial reporting, accounting or business and that the full year guidance provided by the company remains the same.
|Over a month ago|
Afya announces acquisition of UniRedentor for R$225M » 07:4211/0411/04/19
Afya Limited announced…
Afya Limited announced the acquisition, through its wholly-owned subsidiary Afya Participacoes S.A., of 100% of the total share capital of UniRedentor - Sociedade Universitaria Redentor, or UniRedentor. The transaction is subject to antitrust regulatory approval. UniRedentor is a non-profit post-secondary education institution with governmental authorization to offer on-campus, undergraduate courses in medicine in the State of Rio de Janeiro. UniRedentor also offers other health-related undergraduate degrees and graduation programs in medicine and health. In 2018, UniRedentor's gross revenue totaled R$108M and more than 70% came from health-related programs. The aggregate purchase price was R$225M, of which: R$125M will be paid in cash as of the closing date, and R$20M is payable in five equal installments through June 2024, adjusted by the CDI rate. to The acquisition will contribute 112 medical school seats to Afya, increasing Afya's total medical school seats to 1,684 and will fortify Afya's presence in medical graduation courses.
|Over a quarter ago|
Afya initiated with a Buy at UBS » 05:4909/1909/19/19
UBS analyst Maria Tereza…
UBS analyst Maria Tereza Azevedo started Afya with a Buy rating and $29 price target. The company, as Brazil's largest medical education network, is the analyst's favored play in Brazilian higher education. She believes Afya benefits from "attractive" undergraduate medical school industry dynamics and "strong" demand for physician preparatory/specialization programs.
Nine new option listings and one option delisting on August 29th » 08:3008/2908/29/19
AFYA, GSX, LVGO, PSNL, SILK, SNDL, TPTX, PHI
New option listings for…
New option listings for August 29th include Afya Ltd (Class A Stock) (AFYA), GSX Techedu Inc (Class A ADS) (GSX), Livongo Health Inc (LVGO), Roundhill Bitkraft Esports & Digital Entertainment ETF (NERD), Personalis Inc (PSNL), Silk Road Medical Inc (SILK), Sundial Growers Inc (SNDL), Turning Point Therapeutics Inc (TPTX), and Vanguard Russell 1000 Value (VONV). Option delistings effective August 29th include Philippine Long Distance (PHI).
Afya appoints Daulins Emilio as director increasing board to eight » 08:5308/1908/19/19
Afya Limited announced…
Afya Limited announced the appointment of Daulins Emilio to its board of directors as a non-independent director, effective as of August 14, 2019. Emilio is a Managing Director at Bertelsmann Brazil Investments and Head of the Bertelsmann Corporate Center in Brazil. Emilio's appointment increases the size of Afya's board of directors to eight directors.
Afya initiated with an Overweight at Morgan Stanley » 07:5508/1308/13/19
Morgan Stanley analyst…
Morgan Stanley analyst Javier Martinez de Olcoz Cerdan initiated Afya with an Overweight rating and $29.20 price target, calling the company the leading medical education group in Brazil. Afya's competitive advantages, including its medical focus, scale and tech, position it well to consolidate the industry in "the largest and most attractive education segment in Brazil," the analyst stated in his initiation note.
Afya initiated with a Buy at BofA/Merrill » 06:5608/1308/13/19
BofA/Merrill analyst Pedro Mariani initiated Afya with a Buy rating and a price target of $29, saying the stock offers a "winning combination" of "solid and predictable" top-line growth at 13% per year over the past 10 years and a high exposure to a high-quality niche of students. The analyst adds that the value proposition of Afya is further strengthened by its alternative solutions offerings, such as Medcel and IPEMED.
Fly Intel: Top five analyst initiations » 10:1108/0908/09/19
LOVE, MNRO, CECE, AFYA, ATEX
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lovesac (LOVE) initiated with an Outperform at Oppenheimer. 2. Monro (MNRO) initiated with a Market Perform at BMO Capital. 3. CECO Environmental (CECE) resumed with a Buy at Needham. 4. Afya (AFYA) initiated with an Overweight at JPMorgan. 5. Anterix (ATEX) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
Afya initiated with an Overweight at JPMorgan » 06:5608/0908/09/19
JPMorgan analyst Marcelo…
JPMorgan analyst Marcelo Santo started Afya with an Overweight rating and $34 price target. The analyst expects the company to grow "significantly" above Brazilian peers and with lower risk given the "high demand and constrained supply ensuring unit occupation and high prices." He calls Afya Brazil's leading medical higher education institution.